Panacea Biotec Q3 net up fivefold to Rs 43 cr

Image
Press Trust of India New Delhi
Last Updated : Jan 25 2013 | 2:53 AM IST

Panacea Biotec today said its net profit zoomed over fivefold to Rs 42.60 crore for the third quarter ended December 31, 2010, over the same period previous fiscal.

The company had a net profit of Rs 7.34 crore in the same period last fiscal, Panacea Biotec said in a statement.

Its net sales rose to Rs 284.06 crore for the third quarter ended December 31, 2010, compared to Rs 228.10 crore in the same period last fiscal.

"Panacea Biotec continues to register significant and sustainable growth during the quarter and nine months ended December 31, 2010 both in terms of revenues and profits as expected," Panacea Biotec Joint Managing Director Rajesh Jain said.

The company's pharmaceutical formulations segment grew by 12 per cent with a net turnover of Rs 71 crore for the third quarter, as compared to Rs 63.2 crore during the same period previous fiscal.

The vaccine segment grew by 29 per cent with a net turnover of Rs 212.1 crore as compared to Rs 164.4 crore during the same period last fiscal.

Shares of Panacea Biotec today closed at Rs 191.20 on the Bombay Stock Exchange, down 2.40 per cent from its previous close.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 01 2011 | 7:23 PM IST

Next Story